Toronto, Ontario--(Newsfile Corp. - July 6, 2026) - ALZAI Health Corp. (TSXV: ALZI) ("ALZAI" or the "Company"), is pleased to announce the validation of its proprietary artificial intelligence-driven Alzheimer's disease risk identification models using a large-scale U.S. longitudinal healthcare dataset, representing a significant milestone in the Company's potential U.S. commercialization.
The validation demonstrated that ALZAI's risk-stratification models achieved performance on-par with previous validation studies conducted using Israeli healthcare data, supporting management's belief that the Company's technology may have the potential to perform across different healthcare systems and patient populations.
The validation utilized real-world longitudinal healthcare data on more than 1.1 million U.S. patients. The dataset contained approximately 38 million common blood chemistry laboratory test results and over 3 million standard chronic disease diagnostic records collected through routine care representing over 100 million clinical data points.
The U.S. healthcare dataset was licensed from HealthVerity, a leading provider of real-world healthcare data in the United States, and was used to evaluate ALZAI's proprietary artificial intelligence solution across multiple prediction horizons and varying lengths of longitudinal patient history. The validation included blood-test-only, chronic disease diagnoses-only, and combined blood-test-data-and-chronic-disease-diagnoses models. ALZAI utilizes ubiquitous and routine clinical information and basic patient demographics in order to deliver a population-level risk screening solution. HealthVerity did not participate in the development of ALZAI's artificial intelligence models, the validation methodology, the analysis of results, or the conclusions presented by the Company and did not verify, endorse or independently validate the Company's results or conclusions. The validation was based on a licensed historical real-world dataset and specific model assumptions and methodologies, and results may not be replicated in prospective studies, other datasets, other patient populations or real-world clinical implementation.
The validation supports the scalability of ALZAI's Solution across multiple healthcare environments and represents an important milestone as the Company moves towards potential commercialization within the United States. ALZAI believes that demonstrating consistent model performance across independent healthcare datasets strengthens the potential applicability of its technology within U.S. healthcare systems, pharmaceutical research, and population health initiatives. ALZAI's solution is intended to support disease risk identification and is not intended to diagnose Alzheimer's disease or replace clinical judgment.